Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Jan 20;2010(1):CD004036.
doi: 10.1002/14651858.CD004036.pub3.

Glucocorticosteroids for primary sclerosing cholangitis

Vanja Giljaca  1 , Goran Poropat, Davor Stimac, Christian Gluud
Affiliations
Meta-Analysis

Glucocorticosteroids for primary sclerosing cholangitis

Vanja Giljaca et al. Cochrane Database Syst Rev. .

Abstract

Background: Primary sclerosing cholangitis is a chronic cholestatic disease of intrahepatic and extrahepatic biliary ducts, characterised by chronic periductal inflammation and sclerosis of the ducts, which results in segmental stenoses of bile ducts, cholestasis, fibrosis, and ultimately, liver cirrhosis. Patients with primary sclerosing cholangitis are at higher risk of cholangiocarcinoma as well as of colonic neoplasia, since primary sclerosing cholangitis is associated with inflammatory bowel disease in more than 80% of the patients. Several therapeutic modalities have been proposed for primary sclerosing cholangitis, like ursodeoxycholic acid, glucocorticosteroids, and immunomodulatory agents, but none has been successful in reversing the process of the disease. To date, liver transplantation is the only definite therapeutic solution for patients with advanced primary sclerosing cholangitis with liver cirrhosis.

Objectives: To assess the beneficial and harmful effects of glucocorticosteroids for patients with primary sclerosing cholangitis.

Search strategy: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE, and LILACS from their inception until September 2009, as well as reference lists.

Selection criteria: Randomised clinical trials comparing any dose or duration of glucocorticosteroids versus placebo, no intervention, or other immunosuppressive agents. We included trials irrespective of language, blinding, or publication status.

Data collection and analysis: Authors extracted data independently and assessed the methodological quality by the generation of the allocation sequence, allocation concealment, double blinding, follow-up, incomplete outcome data reporting, selective reporting, baseline imbalance, and early stopping. The results of the meta-analyses were presented as relative risks (RR) or mean difference (MD), both with 95% confidence intervals (CI). The primary outcome measures were mortality and liver-related morbidity.

Main results: Two randomised clinical trials were eligible for inclusion. One trial compared biliary lavage with hydrocortisone versus saline in 17 patients. Hydrocortisone tended to increase adverse events (pancreatitis, cholangitis with septicaemia, paranoid ideas, fluid retention) (RR 3.43, 95% CI 0.51 to 22.9) and had no cholangiographic improvement, which led to termination of the trial. The other trial compared budesonide versus prednisone in 18 patients. Patients had statistically significant higher serum bilirubin concentration after treatment with prednisone compared with budesonide (MD 10.4 micromol/litre, 95% CI 1.16 to 19.64 micromol/litre). No other statistically significant effects on clinical or biochemical outcomes were reported on any of the evaluated interventions.

Authors' conclusions: There is no evidence to support or refute peroral glucocorticosteroids for patients with primary sclerosing cholangitis. The intrabiliary application of corticosteroids via nasobiliary tube seems to induce severe adverse effects.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 Biliary lavage with hydrocortisone plus saline versus saline, Outcome 1 Mortality.
1.2
1.2. Analysis
Comparison 1 Biliary lavage with hydrocortisone plus saline versus saline, Outcome 2 Serum alkaline phosphatases.
1.3
1.3. Analysis
Comparison 1 Biliary lavage with hydrocortisone plus saline versus saline, Outcome 3 Serum bilirubin.
1.4
1.4. Analysis
Comparison 1 Biliary lavage with hydrocortisone plus saline versus saline, Outcome 4 Adverse events.
2.1
2.1. Analysis
Comparison 2 Budesonide versus prednisone, Outcome 1 Pruritus.
2.2
2.2. Analysis
Comparison 2 Budesonide versus prednisone, Outcome 2 Fatigue.
2.3
2.3. Analysis
Comparison 2 Budesonide versus prednisone, Outcome 3 Serum bilirubin.
2.4
2.4. Analysis
Comparison 2 Budesonide versus prednisone, Outcome 4 Serum alkaline phosphatases.
2.5
2.5. Analysis
Comparison 2 Budesonide versus prednisone, Outcome 5 Adverse events.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Allison 1986 {published data only}
    1. Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. Journal of Hepatology 1986;3(1):118‐22. [MEDLINE: ] - PubMed
van Hoogstraten 2000 {published data only}
    1. Hoogstraten HJ, Vleggaar FP, Boland GJ, Steenbergen W, Griffioen P, Hop WCJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomised double‐blind pilot study. Belgian‐Dutch PSC Study Group. The American Journal of Gastroenterology 2000;95(8):2015‐22. [MEDLINE: ] - PubMed

References to studies excluded from this review

Angulo 2000 {published data only}
    1. Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. American Journal of Gastroenterology 2000;95(9):2333‐7. - PubMed
Boberg 2003 {published data only}
    1. Boberg KM, Egeland T, Schrumpf E. Long‐term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scandinavian Journal of Gastroenterology 2003;38(9):991‐5. - PubMed
Burgert 1984 {published data only}
    1. Burgert SL, Brown BP, Kirkpatrick RB, LaBrecque DR. Positive corticosteroid response in early sclerosing cholangitis. Gastroenterology 1984;86(5):1037.
Grijm 1986 {published data only (unpublished sought but not used)}
    1. Grijm R, Huibregtse K, Bartelsman J, Mathus‐Vliegen EMH, Dekker W, Tytgat GN. Therapeutic investigations in primary sclerosing cholangitis. Digestive Diseases and Sciences 1986;31(8):793‐8. - PubMed
Lindor 1991 {published data only}
    1. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. The American Journal of Gastroenterology 1991;86(1):57‐61. [MEDLINE: ] - PubMed
Schramm 1999 {published data only}
    1. Schramm C, Schirmacher P, Helmreich‐Becker I, Gerken G, Meyer zum Büschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone and ursodiol in patients with primary sclerosing cholangitis. Annals of Internal Medicine 1999;131:943‐6. - PubMed

Additional references

Ahrendt 1998
    1. Ahrendt SA, Pitt HA, Kalloo AN, Venbrux AC, Klein AS, Herlong HF, et al. Primary sclerosing cholangitis: resect, dilate, or transplant?. Annals of Surgery 1998;227(3):412‐23. [MEDLINE: ] - PMC - PubMed
Burgert 1984
    1. Burgert SL, Brown BP, Kirkpatrick RB, LaBrecque DR. Positive corticosteroid response in early sclerosing cholangitis. Gastroenterology 1984;86(5):1037.
Chapman 2003
    1. Chapman RW. The management of primary sclerosing cholangitis. Current Gastroenterology Reports 2003;5:9‐17. - PubMed
Charatcharoenwitthaya 2006
    1. Charatcharoenwitthaya P, Lindor KD. Pirmary sclerosing cholangitis: diagnosis and management. Current Gastroenterology Reports 2006;8:75‐82. - PubMed
Chen 1984
    1. Chen LY, Goldberg HI. Sclerosing cholangitis: broad spectrum of radiographic features. Gastrointestinal Radiology 1984;9(1):39‐47. - PubMed
Chen 2003
    1. Chen W, Gluud C. Bile acids for primary sclerosing cholangitis (Cochrane review). Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD003626] - DOI - PubMed
Cullen 2005
    1. Cullen SN, Chapman RW. Review article: current management of primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics 2005;21:933‐48. [DOI: 10.1111/j.1365-2036.2005.02407.x] - DOI - PubMed
Donaldson 1991
    1. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991;13(1):129‐33. [MEDLINE: ] - PubMed
Fracchia 2000
    1. Fracchia M, Secreto P, Tabone M, Zaffino C, Pera A, Galatola G. Serum interferon gamma in primary biliary cirrhosis: effect of ursodeoxycholic acid and prednisone therapy alone and in combination. European Journal of Gastroenterology & Hepatology 2000;12(4):463‐8. [MEDLINE: ] - PubMed
Gluud 2009
    1. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2009, Issue 4. Art. No.: LIVER.
Gordon 2008
    1. Gordon FD. Primary sclerosing cholangitis. Surgical Clinics of America 2008;88:1385‐407. [DOI: 10.1016/j.suc.2008.07.010] - DOI - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Colloboration, 2008. Available from www.cochrane‐handbook.org.
ICH‐GCP 1997
    1. International Conference on Harmonisation Expert Working Group. Code of Federal Regulations & International Conference on Harmonization Guidelines. Media: Parexel Barnett, 1997.
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomised trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. [MEDLINE: ] - PubMed
LaRusso 1984
    1. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. The New England Journal of Medicine 1984;310(14):899‐903. [MEDLINE: ] - PubMed
LaRusso 1999
    1. LaRusso NF, Wiesner RH, Ludwig J. Sclerosing cholangitis. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J editor(s). Oxford Textbook of Clinical Hepatology. 2. Vol. II, Oxford: Oxford University Press, 1999:1121‐1130.
Lindor 1986
    1. Lindor KD, Wiesner RH, LaRusso NF, Dickson ER. Chronic active hepatitis: overlap with primary biliary cirrhosis and primary sclerosing cholangitis. In: Czaja AJ, Dickson ER editor(s). Chronic active hepatitis: the Mayo Clinic experience. New York: Marcel Dekker, 1986:171‐85.
Lindor 1987
    1. Lindor KD, Wiesner RH, LaRusso NF. Recent advances in the management of primary sclerosing cholangitis. Seminars in Liver Disease 1987;7(4):322‐7. [MEDLINE: ] - PubMed
Lindor 1991
    1. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. The American Journal of Gastroenterology 1991;86(1):57‐61. [MEDLINE: ] - PubMed
Long 1978
    1. Long RG, Meinhard E, Skinner RK, Varghese Z, Wills MR, Sherlock S. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease. Gut 1978;19(2):85‐90. [MEDLINE: ] - PMC - PubMed
Ludwig 1981
    1. Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981;1(6):632‐40. [MEDLINE: ] - PubMed
Ludwig 1986
    1. Ludwig J, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis. In: Peters RL, Craig JR editor(s). Liver pathology‐contemporary issues in surgical pathology. New York: Churchill Livingstone, 1986:193‐213.
Ludwig 1991
    1. Ludwig J. Small‐duct primary sclerosing cholangitis. Seminars in Liver Disease 1991;11(1):11‐7. [MEDLINE: ] - PubMed
Mitchison 1989
    1. Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot, double‐blind, controlled 1‐year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989;10(4):420‐9. [MEDLINE: ] - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses. Lancet 1998;352(9128):609‐13. [MEDLINE: ] - PubMed
Olerup 1995
    1. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA‐DR and HLA‐DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995;108(3):937‐40. [MEDLINE: ] - PubMed
Pichard 1992
    1. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Molecular Pharmacology 1992;41(6):1047‐55. [MEDLINE: ] - PubMed
Poupon 2000
    1. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. Journal of Hepatology 2000;32(Suppl 1):129‐40. [MEDLINE: ] - PubMed
Quigley 1983
    1. Quigley EM, LaRusso NF, Ludwig J, MacSween RN, Birnie GG, Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983;85(5):1160‐5. [MEDLINE: ] - PubMed
Review Manager 5 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0.. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. JAMA 1995;273(5):408‐12. [MEDLINE: ] - PubMed
Silveira 2008
    1. Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World Journal of Gastroenterology 2008;14(21):3338‐49. - PMC - PubMed
Silveira 2008a
    1. Silveira MG, Lindor KD. Primary sclerosing cholangitis. Canadian Journal of Gastroenterology 2008;22(8):689‐98. - PMC - PubMed
Stiehl 1997
    1. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8‐year prospective study. Journal of Hepatology 1997;26(3):560‐6. [MEDLINE: ] - PubMed
Vacca 2007
    1. Vacca M, Krawczyk M, Petruzzelli M, Sasso RC, Erpecum KJ, Palasciano G, et al. Current treatments of primary sclerosing cholangitis. Current Medical Chemistry 2007;14:2081‐94. - PubMed
van Hoogstraten 2000
    1. Hoogstraten HJ, Vleggaar FP, Boland GJ, Steenbergen W, Griffioen P, Hop WC, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomised double‐blind pilot study. American Journal of Gastroenterology 2000;95(8):2015‐22. [MEDLINE: ] - PubMed
Wee 1985a
    1. Wee A, Ludwig J, Coffey RJ Jr, LaRusso NF, Wiesner RH. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Human Pathology 1985;16(7):719‐26. [MEDLINE: ] - PubMed
Wee 1985b
    1. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?. Annals of Internal Medicine 1985;102(5):581‐7. [MEDLINE: ] - PubMed
Wiesner 1985
    1. Wiesner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985;88(1 Pt 1):108‐14. [MEDLINE: ] - PubMed
Wolfhagen 1994
    1. Wolfhagen FH, Buuren HR, Schalm SW. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. The Netherlands Journal of Medicine 1994;44(3):84‐90. [MEDLINE: ] - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schuly KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601‐5. [MEDLINE: ] - PMC - PubMed

References to other published versions of this review

Chen 2004
    1. Chen W, Gluud C. Clucocorticosteroids for primary sclerosing cholangitis. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004036.pub2.] - DOI - PubMed

MeSH terms

LinkOut - more resources